Compounded tirzepatide in 2026: dual GIP/GLP-1 mechanism, common vial concentrations, FDA enforcement landscape, and how to vet a U.S. supplier responsibly.
Compounded tirzepatide is a non-FDA-approved preparation of the tirzepatide molecule made by a licensed U.S. compounding partner. It is not equivalent to branded tirzepatide drugs from a regulatory standpoint and is supplied for research, investigational, or licensed-professional use only.
Tirzepatide is a dual GIP / GLP-1 receptor agonist — mechanistically distinct from semaglutide — and is the active molecule in two of the most-prescribed metabolic drugs in the United States. Compounded tirzepatide is the same molecule prepared by a licensed U.S. compounding partner. This guide covers the regulatory landscape in 2026, typical presentations, and what buyers should ask any supplier.
Tirzepatide activates two incretin receptors — GIP and GLP-1 — where semaglutide activates only GLP-1. The dual agonism is the mechanistic basis for the broader metabolic effect seen in clinical trials of the branded drugs. The compounded preparation contains the same active molecule.
From a buyer perspective, the molecule's properties — half-life, reconstitution, storage — are similar to semaglutide. The market difference is supply: compounded tirzepatide moved off the FDA shortage list later, and supply tightened more recently.
All peptide products referenced are intended solely for research, investigational, or licensed professional use. They are not FDA-approved and are not intended to diagnose, treat, cure, or prevent any disease. Consult a licensed medical practitioner before any personal or clinical use.
No. Compounded tirzepatide contains the tirzepatide molecule but is not the same FDA-approved product as Mounjaro or Zepbound and is not regulated as such.
Compounded tirzepatide can be legally prepared by a licensed U.S. compounding partner for research, investigational, or licensed professional use, subject to current FDA and state pharmacy regulations. The compliance lane has narrowed since 2024.
We rotate 10 mg, 30 mg, and 60 mg vial presentations based on supply. Members see current concentrations and bulk-direct pricing in the catalog after signing in with a VIP code.
They are mechanistically different — tirzepatide is a dual GIP/GLP-1 agonist; semaglutide is GLP-1 only. The choice depends on the use case, response, and practitioner guidance. See our journal article comparing the two.
Lyophilized vials are kept refrigerated. After reconstitution with bacteriostatic water, most preparations are kept at 2–8°C and used within roughly 28 days. Always defer to the specific compounder's labeled stability window.